Eli Lilly Enters a ~$415M Licensing Agreement with Alchemab Therapeutics for ATLX-1282 to Treat Amyotrophic Lateral Sclerosis (ALS)

Shots:Eli Lilly has entered into a licensing agreement with Alchemab for ATLX-1282 to treat ALS & other neurodegenerative conditionsAs per the deal, Alchemab will receive ~$415M, incl. an upfront payment, potential discovery, development, & commercial payments, as well as royalties, plus will handle early P-I trial activities, with Lilly leading further development &…

ByRidhi RastogiMay 6, 2025

News

SineuGene Therapeutics Reports the US FDA’s IND Clearance of SNUG01 for Amyotrophic Lateral Sclerosis

Shots:The US FDA has granted IND clearance to SNUG01 for ALSSNUG01 will be evaluated in a P-I/IIa dose-escalation & expansion trial to assess its safety, tolerability, & preliminary efficacy in ALS adults; SineuGene to partner with academics & institutions to lead clinical development of SNUG01 SNUG01, a TRIM72-targeted gene therapy, counteracts ALS through…

ByRidhi RastogiApril 3, 2025

INSIGHTS+

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

Shots: Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that leads to the progressive degeneration of nerve cells in the spinal cord and brain Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and the role of patient advocacy groups. Additionally, we highlight the key industry…

ByDipanshu DixitFebruary 25, 2025

VIEWPOINTS

Enhancing Neurodegenerative Care: Stella Sarraf from Spinogenix in an Enlightening Dialogue Exchange with PharmaShots

Shots: With a broad portfolio of candidates in ALS, Alzheimer’s disease, Schizophrenia, and Fragile X Syndrome, Spinogenix initiated the P-II study evaluating SPG302 for the treatment of patients with Alzheimer’s disease SPG302, a synaptic regenerative therapy, is aimed to provide an effective and patient-friendly solution as a daily pill for ALS and Alzheimer’s disease Today…

BySaurabh ChaubeyOctober 14, 2024

VIEWPOINTS

Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN

Shots: Following the strategic collaboration with the Sheffield Institute for Translational Neuroscience (SITraN), Metabolon’s scientific strategic director Kari Wong, engages in an illuminating conversation with PharmaShots The collaboration aims to enhance the understanding of ALS and motor neuron disease (MND) by integrating a comprehensive biomarker approach to provide better diagnostics and therapeutics for these challenging…

BySaurabh ChaubeyApril 8, 2024

INSIGHTS+

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

Shots: To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research To continue the series for the disease of the month, PharmaShots brings this month a summary of the disease Amyotrophic Lateral Sclerosis (ALS), a rare…

ByDipanshu DixitMay 11, 2023

Eli Lilly Enters a ~$415M Licensing Agreement with Alchemab Therapeutics for ATLX-1282 to Treat Amyotrophic Lateral Sclerosis (ALS)

SineuGene Therapeutics Reports the US FDA’s IND Clearance of SNUG01 for Amyotrophic Lateral Sclerosis

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

Enhancing Neurodegenerative Care: Stella Sarraf from Spinogenix in an Enlightening Dialogue Exchange with PharmaShots

Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

Contact US

OUR INFORMATION

FOLLW US

Eli Lilly Enters a ~$415M Licensing Agreement with Alchemab Therapeutics for ATLX-1282 to Treat Amyotrophic Lateral Sclerosis (ALS)

SineuGene Therapeutics Reports the US FDA’s IND Clearance of SNUG01 for Amyotrophic Lateral Sclerosis

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

Enhancing Neurodegenerative Care: Stella Sarraf from Spinogenix in an Enlightening Dialogue Exchange with PharmaShots

Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN

Disease of the Month – Amyotrophic Lateral Sclerosis (ALS)

FOLLW US

Sign Up to Our Newsletter